Ingestion-treatment interval is critical
You should rotate injection sites with every dose, moving at least 12 cm from the previous injection point and alternating between body regions over time
What the Research Says About GLP-1s and HS While clinical research is still in early stages, several studies support what many of us in the HS community have seen anecdotally: A 2024 study of patients with HS found that semaglutide reduced the frequency of flares and systemic inflammationflaring decreased from once every 8.5 weeks to once every 12 weeks
For women, the arrangements that do not respond are the ones already in place, where any first impression occurred long ago and where weight is one characteristic embedded in a much richer stock of information
For instance, a clinical trial involving more than 1,900 adults with obesity found that those who took oral Semaglutide GLP-1 for 68 weeks lost an average of 12.4% of their body weight
The early inhibitory analogs involved substitutions or deletions at these two positions